FGF21 negatively affects long-term female fertility in mice.
FGF21
Fertility
High-fat diet
Non-alcoholic fatty liver disease
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
22
07
2022
revised:
02
09
2022
accepted:
04
11
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Obesity and associated liver disease are a growing public health concern. Pharmacological agents to treat non-alcoholic fatty liver disease are limited. FGF21, a hormone secreted by the liver and potent metabolic modulator, is a promising therapeutic target for this indication with several analogs currently in clinical development. However, concerns about a negative effect of FGF21 on female fertility have not been fully addressed. After induction of obesity, female C57BL/6N mice received a 7-day course of subcutaneously administered FGF21. Control groups received either high-fat diet (HFD) or a normal diet (ND). The mothers were then mated with lean males for 12 weeks. The estrous cycle was recorded for two weeks after breeding. The metabolic phenotype, liver steatosis and reproductive organs were assessed at sacrifice 14 weeks after treatment. A short-course treatment of FGF21 leads to weight reduction during treatment but has no long-term impact on liver steatosis. A treatment with FGF21 leads to a reduction in the number of pregnancies (0 vs 1, A short-term treatment with FGF21 has a long-term effect on female fertility in mice. This represents a potential safety concern for FGF21 analogs currently in clinical development. Reproductive health outcomes should be included in upcoming clinical trials.
Identifiants
pubmed: 36406708
doi: 10.1016/j.heliyon.2022.e11490
pii: S2405-8440(22)02778-5
pmc: PMC9667250
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e11490Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cell Metab. 2016 Mar 8;23(3):427-40
pubmed: 26959184
Trends Endocrinol Metab. 2019 Aug;30(8):491-504
pubmed: 31248786
Biochem Biophys Res Commun. 2019 Nov 12;519(3):475-480
pubmed: 31526570
Front Cardiovasc Med. 2021 Mar 31;8:655575
pubmed: 33869312
Physiol Rev. 2000 Jan;80(1):1-29
pubmed: 10617764
Mol Metab. 2016 May 18;5(8):690-698
pubmed: 27656406
Endocrinology. 2008 Dec;149(12):6018-27
pubmed: 18687777
Cell Metab. 2010 Sep 8;12(3):295-305
pubmed: 20816095
Elife. 2012 Oct 15;1:e00065
pubmed: 23066506
Reprod Biol Endocrinol. 2018 Mar 9;16(1):22
pubmed: 29523133
Nat Med. 2021 Jul;27(7):1262-1271
pubmed: 34239138
Curr Protoc Neurosci. 2009 Jul;Appendix 4:Appendix 4I
pubmed: 19575469
Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10
pubmed: 33965578
Sci Rep. 2018 Mar 9;8(1):4241
pubmed: 29523796
Curr Biol. 2019 Feb 18;29(4):592-604.e4
pubmed: 30744968
Cell Metab. 2016 Feb 9;23(2):335-43
pubmed: 26724858
Gastroenterology. 2018 Dec;155(6):1828-1837.e2
pubmed: 30144434
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Cell Metab. 2007 Jun;5(6):415-25
pubmed: 17550777
PLoS One. 2012;7(4):e35538
pubmed: 22514749
Nat Med. 2013 Sep;19(9):1153-6
pubmed: 23933983
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Biomedicines. 2022 Jan 26;10(2):
pubmed: 35203484
Sci Rep. 2019 Mar 26;9(1):5153
pubmed: 30914732
Endocrinology. 2004 Mar;145(3):1238-47
pubmed: 14670988
Nat Rev Endocrinol. 2020 Nov;16(11):654-667
pubmed: 32764725
Exp Gerontol. 1981;16(5):393-8
pubmed: 7318970
Fertil Res Pract. 2020 Mar 14;6:5
pubmed: 32190339
J Bone Miner Res. 2020 Apr;35(4):738-752
pubmed: 31800971
Cell Metab. 2014 Oct 7;20(4):670-7
pubmed: 25130400
J Bone Miner Res. 2017 Apr;32(4):834-845
pubmed: 27505721
Expert Opin Investig Drugs. 2020 Feb;29(2):125-133
pubmed: 31899984
J Am Assoc Lab Anim Sci. 2015 Jul;54(4):368-71
pubmed: 26224435
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3143-8
pubmed: 22315431
J Hepatol. 2015 May;62(5):1148-55
pubmed: 25477264
JHEP Rep. 2021 Aug 08;3(6):100346
pubmed: 34667947
Lancet. 2019 Dec 22;392(10165):2705-2717
pubmed: 30554783
Int J Obes (Lond). 2018 Jun;42(6):1151-1160
pubmed: 29892039
Front Endocrinol (Lausanne). 2020 Dec 14;11:601290
pubmed: 33381084
J Endocr Soc. 2021 Feb 01;5(4):bvab010
pubmed: 33733019
Exp Physiol. 2020 Apr;105(4):622-631
pubmed: 31977105
Hepatology. 2019 Dec;70(6):1885-1888
pubmed: 31520407
Endocrinol Metab (Seoul). 2018 Jun;33(2):273-277
pubmed: 29947182
Nat Med. 2013 Sep;19(9):1147-52
pubmed: 23933984